Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 1
2013 1
2014 1
2018 1
2019 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Host immunological response and factors associated with clinical outcome in patients with the novel influenza A H7N9 infection.
Shen Z, Chen Z, Li X, Xu L, Guan W, Cao Y, Hu Y, Zhang J. Shen Z, et al. Clin Microbiol Infect. 2014 Aug;20(8):O493-500. doi: 10.1111/1469-0691.12505. Epub 2014 Jan 21. Clin Microbiol Infect. 2014. PMID: 24350809 Free article.
To assess the immunological and viral factors associated with disease severity, viral RNA and inflammatory cytokines were quantified for 18 H7N9 patients in Shanghai, China. Detailed clinical information was collected and clinical laboratory inv …
To assess the immunological and viral factors associated with disease severity, viral RNA and inflammatory cytokines were quan …
Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008-2009 winter.
Blanchon T, Mentré F, Charlois-Ou C, Dornic Q, Mosnier A, Bouscambert M, Carrat F, Duval X, Enouf V, Leport C; Bivir Study Group. Blanchon T, et al. Clin Microbiol Infect. 2013 Feb;19(2):196-203. doi: 10.1111/j.1469-0691.2011.03751.x. Epub 2012 Jan 20. Clin Microbiol Infect. 2013. PMID: 22264308 Free article.
Oseltamivir or zanamivir are effective in outpatients with seasonal influenza; however, factors associated with response have been incompletely described. During the 2008/2009 epidemic, in a randomized trial for influenza
Oseltamivir or zanamivir are effective in outpatients with seasonal influenza; however, factors associated
Delayed oseltamivir plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury correlated with repressed NLRP3 inflammasome activation and inflammatory cell infiltration.
Jia X, Liu B, Bao L, Lv Q, Li F, Li H, An Y, Zhang X, Cao B, Wang C. Jia X, et al. PLoS Pathog. 2018 Nov 13;14(11):e1007428. doi: 10.1371/journal.ppat.1007428. eCollection 2018 Nov. PLoS Pathog. 2018. PMID: 30422993 Free PMC article.
Here, delayed oseltamivir treatment was used to mimic clinical settings on lethal influenza A (H1N1) pdm09 virus (pH1N1) infection mice model. ...Therefore, treatment with sirolimus as an adjuvant along with oseltamivir may be a promising immunomodulat …
Here, delayed oseltamivir treatment was used to mimic clinical settings on lethal influenza A (H1N1) pdm09 virus (pH1N1 …
Excess mortality is associated with influenza A (H1N1) in patients with severe acute respiratory illness.
Lobo SM, Watanabe ASA, Salomão MLM, Queiroz F, Gandolfi JV, de Oliveira NE, Covello LHS, Sacillotto GH, de Godoy LG, Simões ES, Frini ICM, Da Silva Teixeira RER, Furlan NP, Dutra KR, Nogueira ML. Lobo SM, et al. J Clin Virol. 2019 Jul;116:62-68. doi: 10.1016/j.jcv.2019.05.003. Epub 2019 May 8. J Clin Virol. 2019. PMID: 31103803
Influenza A (H1N1) 2009 (A/H1N1), influenza A H3N2, and influenza B were tested in all patients by RT-PCR. ...CONCLUSIONS: Hospital mortality associated with influenza H1N1-associated SARI and ARDS continued to be high years
Influenza A (H1N1) 2009 (A/H1N1), influenza A H3N2, and influenza B were tested in all patients by RT-PCR
Antibody response of healthy children to pandemic A/H1N1/2009 influenza virus.
Esposito S, Daleno C, Tagliabue C, Scala A, Picciolli I, Taroni F, Galeone C, Baldanti F, Principi N. Esposito S, et al. Virol J. 2011 Dec 30;8:563. doi: 10.1186/1743-422X-8-563. Virol J. 2011. PMID: 22208497 Free PMC article.
Aims of this study were to analyse antibody responses and the factors associated with high antibody titres in a cohort of children with naturally acquired A/H1N1/2009 influenza infection confirmed by reverse-transcriptase polymerase chain reacti …
Aims of this study were to analyse antibody responses and the factors associated with high antibody titres in a cohort …
Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant.
Abdel-Rahman SM, Newland JG, Kearns GL. Abdel-Rahman SM, et al. Paediatr Drugs. 2011 Feb 1;13(1):19-31. doi: 10.2165/11536950-000000000-00000. Paediatr Drugs. 2011. PMID: 21162598 Review.
This drug is available in oral solid and liquid formulations, has excellent peroral bioavailability in adults, and generally has a very favorable safety profile. Many observational studies indicate that oseltamivir treatment is associated with symptomatic improvemen …
This drug is available in oral solid and liquid formulations, has excellent peroral bioavailability in adults, and generally has a very favo …
Feedback